Question for written answer E-002597/2019
to the Commission
Rule 138
Pascal Arimont (PPE)

Subject: Added value of new medicines and EMA authorisation procedures

A study by scientists at the Institute for Quality and Efficiency in Health Care (IQWiG), published in the British Medical Journal in July this year (https://www.bmj.com/company/newsroom/no-evidence-of-added-benefit-for-most-new-drugs-say-researchers/), shows that, in the case of many newly authorised medicines placed on the German market, there is no evidence of any added benefit compared to standard drugs. In total, the Institute examined 216 medicines which had been newly authorised between 2011 and 2017. 58% of them were found to lack any added value.

Is the Commission aware of the findings and recommendations of this study, and will it draw any conclusions from them for the European Medicines Agency's authorisation procedures?